Literature DB >> 21670759

Pain: MAPK inhibitor shows promise in clinical trial for neuropathic pain.

Katie Kingwell.   

Abstract

Entities:  

Year:  2011        PMID： 21670759     DOI： 10.1038/nrneurol.2011.84

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  1 in total

1.  Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury.

Authors:  Praveen Anand; Ravikiran Shenoy; Joanne E Palmer; Amanda J Baines; Robert Y K Lai; Jonathan Robertson; Nick Bird; Thor Ostenfeld; Boris A Chizh
Journal:  Eur J Pain       Date:  2011-05-14       Impact factor: 3.931
  1 in total
  1 in total

1.  Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion.

Authors:  A Csáti; L Edvinsson; L Vécsei; J Toldi; F Fülöp; J Tajti; K Warfvinge
Journal:  J Headache Pain       Date:  2015-12-01       Impact factor: 7.277
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.